Covered recipient · General Payments record
PENELOPE PAULEY
Allopathic & Osteopathic Physicians Pediatrics Pediatric Endocrinology
General Payments · PY2018–2024
$2,191.65
- Reported across 85 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $463.95 | 15 |
| Education | $32.27 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $191.17 | 5 |
| SANOFI-AVENTIS U.S. LLC | $130.96 | 2 |
| Eton Pharmaceuticals, Inc. | $37.47 | 1 |
| Tandem Diabetes Care, Inc. | $37.37 | 2 |
| TOLMAR, INC. | $36.43 | 2 |
| PFIZER INC. | $25.20 | 1 |
| Ascendis Pharma Inc | $15.16 | 1 |
| Endo USA, Inc. | $13.07 | 1 |
| BETA BIONICS, INC. | $9.39 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Ascendis Pharma Inc | $15.16 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133844100 | CMS |
| BETA BIONICS, INC. | $9.39 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087887999 | CMS |
| Endo USA, Inc. | $13.07 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138586054 | CMS |
| Eton Pharmaceuticals, Inc. | $37.47 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108021350 | CMS |
| Novo Nordisk Inc | $32.27 | 04/23/2024 | Education | Undisputed | 01/23/2026 | 1096987684 | CMS |
| Novo Nordisk Inc | $105.00 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096769178 | CMS |
| Novo Nordisk Inc | $13.13 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096950887 | CMS |
| Novo Nordisk Inc | $25.94 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097542766 | CMS |
| Novo Nordisk Inc | $14.83 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097596841 | CMS |
| PFIZER INC. | $25.20 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131104829 | CMS |
| SANOFI-AVENTIS U.S. LLC | $112.48 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139869063 | CMS |
| SANOFI-AVENTIS U.S. LLC | $18.48 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139869191 | CMS |
| Tandem Diabetes Care, Inc. | $24.88 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138746011 | CMS |
| Tandem Diabetes Care, Inc. | $12.49 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138745953 | CMS |
| Tolmar, Inc. | $15.66 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138712240 | CMS |
| Tolmar, Inc. | $20.77 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138711140 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.